HAS2 and prostate cancer: Overexpression of HA synthase 2 (HAS2) increases receptor tyrosine kinase-dependent signaling in breast and colon cancer cells [10–13], whereas antisense-mediated suppression of HAS2 inhibits tumorigenesis and progression of breast and prostate cancers [14, 15].